ARCALYST revenue growth of 62% for full-year 2025 was primarily driven by the expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment immediately following NSAID and colchicine failure. Management attributes commercial success to a fundamental shift in the treatment paradigm, supported by the 2025 ACC clinical guidance which ratified IL-1 inhibition as a preferred second-line approach. The company is leveraging its profitable ARCALYST franchise to fund strategic investments in ...

Kiniksa outlined several commercial priorities for 2026, including physician education and marketing initiatives designed to broaden awareness and support earlier use in the disease course. Moat said the company plans to:Management attributed ARCALYST’s growth primarily to expanding adoption of IL-1 pathway inhibition as a second-line treatment immediately after failure of NSAIDs and colchicine. Moat pointed to the publication of the 2025 ACC Concise Clinical Guidance , which he said recommends IL-1 pathway ...